Top 5 Biotech Companies To Own In Right Now: Wajax Corp (WJX)
Wajax Corporation (Wajax), is engaged in the sale and after-sales parts and service support of equipment, power systems and industrial components. Wajax�� three business divisions include equipment,power systems and industrial components. Its equipment division is engaged in the distribution, rental, modification and servicing of mobile equipment from manufacturers. It Power Systems is engaged in the distribution, rental and servicing of engines, transmissions and generators for on-highway, off-highway and electric power generation applications. Industrial components is engaged in the distribution, servicing, custom design and assembly of industrial components for in-plant customers and original equipment manufacturers. The Company�� products include excavators, lift trucks, mining trucks and shovels, forest harvesting equipment, utility equipment, loader backhoes, container handlers, cranes, diesel and natural gas engines, transmissions and power generators and bearings. Advisors' Opinion:- [By John Heinzl]
For example, BMO Nesbitt Burns analyst Bert Powell recently raised his price target on Wajax (WJX) to $41.50 from $35.50 because, as he explained in a note, he believes the company is poised for a recovery. The new target reflects his expectation that the stock will trade at 11 times his 2015 earnings per share estimate of $3.77��ts average P/E multiple historically.
Top 5 Diversified Bank Companies To Watch For 2014: Cardica Inc.(CRDC)
Cardica, Inc. engages in the development of an endoscopic microcutter product line for use by thoracic, bariatric, colorectal, and general surgeons primarily in the United States and internationally. Its microcutter product line under development includes Microcutter XPRESS 30, a multi-fire endolinear microcutter device based on the company?s proprietary ?staple-on-a-strip? technology; Microcutter XPRESS 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line; Microcutter XCHANGE 30, a cartridge based microcutter device; Microcutter FLEXCHANGE 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling; and Microcutter XPRESS 60, a cutting and stapling device for the bariatric and thoracic surgery markets. The company also designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery. It offers C-Port Distal Anas tomosis Systems, such as C-Port xA Anastomosis System to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis System to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; C-Port X-CHANGE System, a cartridge-based reloadable C-Port system; and PAS-Port Proximal Anastomosis System to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. Cardica, Inc. sells its products through direct sales force, as well as through independent distributors and manufacturers? representatives. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood C ity, California.
Advisors' Opinion:- [By Bryan Murphy]
Neither Acorn Energy Inc. (NASDAQ:ACFN) nor Cardica, Inc. (NASDAQ:CRDC) may look all that compelling with just a passing glance. The longer one examines CRDC and ACFN, however - and really gets a grasp of their underlying stories - the more compelling each one becomes. In fact, newcomers may want to go ahead and put both budding stocks on their watchlists, if not in their portfolios.
Top 5 Diversified Bank Companies To Watch For 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Ben Levisohn]
The stock market has dropped today as global economic disappointed and investors abandon some of the market’s highest-flying stocks, including Netflix (NFLX), Alexion Pharmaceuticals (ALXN), Facebook (FB), Mylan (MYL) and Michael Kors (KORS).
- [By Diane Alter]
Statin drugs are already a profitable niche in the drug market. But the biggest winners will be makers of lower-priced generics. Those include Mylan Labs (MYL) and Teva Pharmaceuticals (TEVA).
- [By Sean Williams]
Veloci-Raptor time?
First up is Raptor Pharmaceuticals (NASDAQ: RPTP ) with Procysbi (previously known as RP-103), its oral delayed and extended-release medication to treat nephropathic cystinosis. In trials, Procysbi proved to be non-inferior to the only other FDA-approved treatment for nephropathic cystinosis, known as Cystagon from Mylan (NASDAQ: MYL ) .
Top 5 Diversified Bank Companies To Watch For 2014: Fresenius Medical Care AG & Co KGaA (FME)
Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services. Its dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, the Company sells dialysis products to other dialysis service providers. The Company operates in two business segments: North America and International. The North America segment consists of Renal Therapy Group and Fresenius Medical Services. The International segment consists of Europe and Latin America and one Asia-Pacific unit. During the year ended December 31, 2010, the Company's subsidiary, U.S. Vascular Access Holdings, LLC, completed the acquisition of National Vascular Care Inc.; it acquired a total of 168 existing clinics, and acquired Gambro AB�� peritoneal dialysis (PD) business. The Company has a total of 1000 subsidiaries worldwide. Advisors' Opinion:- [By Alex Wayne]
Fresenius Medical Care AG (FME) fell the most in more than four years in Frankfurt after the U.S. government proposed cutting payments to kidney dialysis center operators by 9.4 percent next year.
No comments:
Post a Comment